Answers are grounded in this paper and cite their sources.
Background: Pre-eclampsia and eclampsia remain among the leading causes of maternal death and severe maternal and perinatal morbidity worldwide. Mortality is concentrated in low-resource settings, while the diagnostic boundaries of the syndrome, its presumed mechanisms and the evidence for preventive and therapeutic strategies have changed considerably during the past decade. Aims and Scope: This critical narrative review appraises evidence on classification and burden, pathophysiological heterogeneity, the cerebral basis of eclampsia, risk prediction and diagnosis, prevention, acute management, health-system delivery, and postpartum and lifelong consequences. Its central question is how far current certainty extends across disease subtypes and resource settings. Methods: Literature published between 1 January 1990 and 16 August 2026 was identified through structured searches of bibliographic databases, authoritative guideline sources and citation tracking. Studies were appraised qualitatively for design, internal validity, consistency, precision and transferability, and the evidence was synthesised thematically. Findings: The strongest evidence supports magnesium sulphate for the prevention and treatment of eclamptic seizures, low-dose aspirin started early in pregnancy in women identified as being at high risk of preterm pre-eclampsia, prompt treatment of severe hypertension, and planned delivery at term. Planned delivery in late preterm disease reduces maternal morbidity at the cost of short-term neonatal morbidity in high-income settings. Angiogenic imbalance is the best-characterised mediator of the maternal syndrome and supports reliable short-term rule-out testing, yet benefits for hard perinatal outcomes have not been demonstrated consistently. Recent synthesis restricted to trustworthy trials has substantially weakened confidence in calcium supplementation. Term and postpartum disease, eclampsia without antecedent warning signs, and the causal contribution of the maternal cardiovascular system remain incompletely explained. Much residual mortality reflects failures to deliver proven care rather than an absence of efficacious interventions. Implications: Priorities include phenotype-specific trials, outcome-based evaluation of biomarkers, implementation research in high-burden settings and structured postpartum cardiovascular follow-up. Conclusion: Pre-eclampsia is better understood as a family of placental and maternal cardiovascular pathways converging on a shared maternal syndrome. Further progress depends on matching interventions to these pathways and on delivering effective care equitably.
No takes yet. Share an insight, caveat, or question.
Ndeh et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: